Aurinia Pharmaceuticals Inc (AUPH) Expected to Post Quarterly Sales of $60,000.00
Analysts expect Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) to announce sales of $60,000.00 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Aurinia Pharmaceuticals’ earnings, with the highest sales estimate coming in at $100,000.00 and the lowest estimate coming in at $30,000.00. Aurinia Pharmaceuticals posted sales of $30,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 100%. The company is expected to announce its next earnings results on Friday, November 3rd.
According to Zacks, analysts expect that Aurinia Pharmaceuticals will report full year sales of $60,000.00 for the current fiscal year, with estimates ranging from $120,000.00 to $500,000.00. For the next fiscal year, analysts expect that the company will post sales of $240,000.00 per share, with estimates ranging from $100,000.00 to $500,000.00. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.10. Aurinia Pharmaceuticals had a negative net margin of 16,648.93% and a negative return on equity of 28.61%. The company had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.06 million.
A number of analysts recently issued reports on the company. Vetr downgraded Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating and set a $6.64 price target for the company. in a research report on Wednesday, September 6th. BidaskClub downgraded Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Zacks Investment Research upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research report on Tuesday, August 15th. Finally, Cantor Fitzgerald set a $14.00 price target on Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 11th. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $9.79.
Shares of Aurinia Pharmaceuticals (NASDAQ AUPH) traded up 1.13% on Friday, hitting $6.27. 400,990 shares of the company traded hands. The stock’s market capitalization is $523.45 million. The firm’s 50 day moving average price is $6.22 and its 200-day moving average price is $6.72. Aurinia Pharmaceuticals has a 1-year low of $2.02 and a 1-year high of $10.54.
Large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada lifted its position in shares of Aurinia Pharmaceuticals by 8.6% during the second quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 1,341 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Aurinia Pharmaceuticals during the first quarter worth $155,000. Cutler Capital Management LLC bought a new stake in shares of Aurinia Pharmaceuticals during the second quarter worth $184,000. Investment Centers of America Inc. bought a new stake in shares of Aurinia Pharmaceuticals during the second quarter worth $184,000. Finally, Two Sigma Securities LLC bought a new stake in shares of Aurinia Pharmaceuticals during the first quarter worth $240,000. Institutional investors and hedge funds own 27.76% of the company’s stock.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.